T-knife has set out to revolutionize the TCR landscape with its unique and proprietary transgenics HuTCR mouse platform to produce fully human TCRs. These TCRs mimic the properties of virus-specific TCRs, avoiding immunological tolerance to self tumor antigens in humans.
T-knife’s TCRs do not require additional modification. They are naturally selected in vivo for optimal affinity and specificity.
T-knife was founded in 2018 by Thomas Blankenstein, Elisa Kieback and Holger Specht as spin-off from Max-Delbruck Center for Molecular Medicine with support of Charité University Hospital in Berlin/Germany and the mission to bring novel, T-cell receptor-based therapeutics to market. Based on the unparalleled T-cell immunology expertise of its founders and the unique and proprietary HuTCR platform, the Company discovers fully-human TCRs which have the potential to achieve superior safety and efficacy.
The Company has demonstrated preclinical proof-of-concept with multiple TCRs. In addition, T-knife has validated the platform for over 90 undisclosed cancer targets and has several drug candidates currently in preclinical development.